跳至主要内容
临床试验/ACTRN12616000140459
ACTRN12616000140459已完成未知

Effect of inhaled beta-2-agonist salbutamol on exhaled nitric oxide in chronic obstructive pulmonary disease

niversity of Otago0 个研究点目标入组 20 人开始时间: 2016年2月5日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
45 Years 至 o limit(—)
性别
All

入选标准

  • Diagnosis of chronic obstructive pulmonary disease, aged 45 years or older, smoking history of more than 10 pack years, taking inhaled salbutamol as required, post-bronchodilator FEV1/FVC of less than 70% and FEV1 < 80% predicted.

排除标准

  • No exacerbations or use of antibiotics in the two weeks preceding study participation. No patients with diagnosed lung cancer, bronchiectasis, or other significant co-morbidity. No patients unable to perform the 50mL/s exhaled nitric oxide manoeuvres in accordance with American Thoracic Society guidelines

研究者

相似试验